Press Releases

GlobeNewswire, Inc.

Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, Texas and DURHAM,...

The Office of Attorney General Connecticut

05/19/2026 Coalition challenges unlawful rule that could restrict access to advanced education and worsen workforce shortages (Hartford, CT) — Attorney General William Tong today joined a coalition of attorneys general in filing a lawsuit against...

GlobeNewswire, Inc.

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors of an upcoming deadline...

GlobeNewswire, Inc.

Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast...

GlobeNewswire, Inc.

LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient...

GlobeNewswire, Inc.

NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against SES AI...

GlobeNewswire, Inc.

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that...

GlobeNewswire, Inc.

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- On April 26, 30 students and six chaperones from the Boston area returned from Panama after a week spent finishing two new classrooms, painting four murals, and refurbishing two playgrounds, working...

GlobeNewswire, Inc.

Austin, TX, USA, May 06, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “RNA Targeting Small Molecule Drug Discovery Market Size, Trends and Insights By Indication (Cancer, Metabolic Diseases, Infectious...

GlobeNewswire, Inc.

Boston, May 06, 2026 (GLOBE NEWSWIRE) -- Global corporate investment in artificial intelligence reached $218 billion in 2024, representing a 22% increase from the previous year, as pharmaceutical companies accelerate drug discovery timelines and...

GlobeNewswire, Inc.

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced results for its second quarter fiscal year 2026. Second Quarter Highlights Second Quarter Diluted EPS of $1.27 and Adjusted EPS of $1.61 Reinforcement Materials...

GlobeNewswire, Inc.

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with...

GlobeNewswire, Inc.

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on...

GlobeNewswire, Inc.

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 – Phase 3 DME clinical trials, COMO and CAPRI, rapidly advancing with over one-third of patients enrolled; enrollment completion expected in Q3...

EIN Presswire

Next 8 Weeks Will Be A Pivotal Test For Apartment Demand BOSTON, MA, UNITED STATES, April 29, 2026 /⁨EINPresswire.com⁩/ -- Boston Pads, the industry leader in tracking real-time rental market data in Boston, reports that Boston’s citywide...

GlobeNewswire, Inc.

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in...

GlobeNewswire, Inc.

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: First quarter 2026 revenue of...

GlobeNewswire, Inc.

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026 Initiation of Phase 1 study of...

GlobeNewswire, Inc.

Boston, MA, May 05, 2026 (GLOBE NEWSWIRE) -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today revealed that Stairhopper Movers has been ranked No. 80 on its sixth annual Inc....

EIN Presswire

BackPocket Talent and CareerGPT bring AI workforce planning to small businesses, helping leaders understand evolving roles, essential skills, and team needs.